Tissue | Time point | Diseases and functions | Annotation | P | Molecule |
Liver | 1 h | ND | |||
6 h | ND | ||||
24 h | Cancer, endocrine system disorders | Asymptomatic stage medullary thyroid carcinoma | 2.9E−03 | EGFR,NTRK2 | |
Cancer, endocrine system disorders | Locoregional medullary thyroid carcinoma | 2.9E−03 | EGFR,NTRK2 | ||
Cancer, endocrine system disorders | Metastatic medullary thyroid carcinoma | 2.9E−03 | EGFR,NTRK2 | ||
Cancer, endocrine system disorders | Progressive medullary thyroid cancer | 2.9E−03 | EGFR,NTRK2 | ||
7 d | Endocrine system disorders | Benign thyroid disease | 3.0E−03 | ALB,DIO1,GC | |
Developmental disorder, endocrine system disorders, hereditary disorder, metabolic disease | Dysalbuminemic hyperthyroxinemia | 4.0E−03 | ALB | ||
Endocrine system disorders, metabolic disease | Hyperthyroidism | 6.1E−03 | DIO1,GC | ||
Amino acid metabolism, molecular transport, small-molecule biochemistry | Transport of l-triiodothyronine | 8.1E−03 | Slco1a4 | ||
Amino acid metabolism, drug metabolism, molecular transport, small-molecule biochemistry | Transport of levothyroxine | 1.2E−02 | Slco1a4 | ||
Amino acid metabolism, molecular transport, small-molecule biochemistry | Efflux of l-triiodothyronine | 1.6E−02 | ALB | ||
Amino acid metabolism, drug metabolism, molecular transport, small-molecule biochemistry | Efflux of levothyroxine | 1.6E−02 | ALB | ||
Small-molecule biochemistry | Inactivation of TH | 1.6E−02 | DIO1 | ||
Endocrine system development and function, organ development | Activation of parathyroid gland | 2.0E−02 | GC | ||
Endocrine system development and function, small-molecule biochemistry | Metabolism of TH | 2.8E−02 | DIO1 | ||
Organ development | Function of thyroid gland | 3.2E−02 | DIO1 |
ND = not detected.
Pathways related to TH-associated diseases and functions were generated with IPA software; analysis was performed using NEXUS Expression output files of significantly regulated transcripts in response to 1.7–1.8 kBq of 211At at respective time points.